Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney Disease

Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces the publication of new real-world evidence (RWE) in Primary Care and Community Health demonstrating the Company’s KidneyIntelX bioprognostic™ test resulted in changed clinical decision making for patients in the early-stage of diabetic kidney disease (DKD) being cared for within the Mount Sinai Health System’s Population Health Ambulatory Pharmacy and Condition Management programs.

Blood Metabolite Levels May Help Identify Diabetic Kidney Disease

Noninvasive measurement may provide alternative to diagnostic kidney biopsy Charlottesville, Va. (June 24, 2019)—Metabolomics, the study of small molecules the body produces during metabolism (metabolites) may be a future key to identifying diabetes-related kidney disease. The finding will be presented…